Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe—The HEALTH Model
Bengt Jönsson(Stockholm School of Economics), Fernando Antoñanzas(Universidad de La Rioja), Stephan Lüders(St. Josefs-Hospital Cloppenburg), Peter Lindgren(Swedish Institute), B Gradl(Solvay (Germany)), Joachim Schrader(Klinikum Oldenburg), Hans‐Christoph Diener(Vivantes Klinikum), Wolfgang Greiner(Bielefeld University), York Zöllner(Solvay (Germany))
Cited by 19
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
The size and burden of mental disorders and other disorders of the brain in Europe 2010
|European Neuropsychopharmacology|2011|3.8k
Assessment of fracture risk
|Osteoporosis International|2004|1.2k
Barriers and Strategies in Guideline Implementation—A Scoping Review
|Healthcare|2016|946
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
|Quality of Life Research|2010|903